Last reviewed · How we verify
Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic
Methods: Single-center pilot study included PCR+ SARS-CoV2-patients, hospitalized from April to May 2020 in Puebla, Mexico. Comparative treatment with steroids plus CsA or steroids. Mild, moderate or severe pneumonia was measured by clinical, laboratory tests, lung damage score by computed tomography, and score for clinical improvement. Death rate was evaluated at 28 days.
Details
| Lead sponsor | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | UNKNOWN |
| Enrolment | 200 |
| Start date | 2020-09 |
| Completion | 2020-09-30 |
Conditions
- COVID 19 Pneumonia
Interventions
- Cyclosporin A
Primary outcomes
- Number of days to clinical improvement until hospital discharge or death. — 28 days.
Improvement of patients, defined by the following parameters: lower oxygen requirements (2 liters per minute, or less), absence of fever by three consecutive days, respiratory rate \<22, a decrease of 50% or more in the C reactive protein on admission, and length of hospital stay.
Countries
Mexico